In particular, recent studies have shown that decreased levels of BCHE are associated with poor prognosis in several cancers (e.g., pancreatic, gastric, and colorectal cancers).13–15 Furthermore, findings have shown the combination of serum Alb and BCHE levels to be useful for predicting the prognosis for patients with colorectal cancer because this biomarker is related to preoperative nutritional status.16 This evidence concerns the gene BCHE and cancer.